In addition, TIGIT/CD155 engagement down-regulated the functions of CD4+ T cells from patients with SLE in vitro indicating TIGIT as a negative regulator of CD4+ T cell function in SLE and a potential therapeutic target for the treatment of this disease (79). The gene discussed is PVR; the disease is systemic lupus erythematosus.